For patients on treatment at year 7 , 99.3 % maintained viral suppression ( HBV DNA < 69 IU/mL ) , 80.0 % achieved serum alanine aminotransferase normalization , and in HBeAg-positive patients , 84/154 ( 54.5 % ) and 25/154 ( 11.8 % ) achieved HBeAg and HBsAg loss , respectively .